Aduro is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro's technology platforms, which are designed to harness the body's natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases.
December 12, 2017 Aduro Biotech Provides Update on CRS-207 Programs
Events & Presentations
December 12, 2017Aduro Biotech Inc. Company Update
Data provided by Nasdaq. Minimum 15 minutes delayed.